Lexaria Bioscience Corp (LEXX)
3.15
+0.01
(+0.32%)
USD |
NASDAQ |
May 17, 16:00
2.99
-0.16
(-5.08%)
After-Hours: 20:00
Lexaria Bioscience Cash from Financing (Quarterly): 3.453M for Feb. 29, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| February 29, 2024 | 3.453M |
| November 30, 2023 | 1.819M |
| August 31, 2023 | -0.1217M |
| May 31, 2023 | 1.711M |
| February 28, 2023 | 0.00 |
| November 30, 2022 | 0.00 |
| August 31, 2022 | -0.0112M |
| May 31, 2022 | -0.0112M |
| February 28, 2022 | -0.0112M |
| November 30, 2021 | -0.011M |
| August 31, 2021 | 4.004M |
| May 31, 2021 | -0.011M |
| February 28, 2021 | 9.435M |
| November 30, 2020 | -0.0088M |
| August 31, 2020 | -0.0892M |
| May 31, 2020 | 1.916M |
| February 29, 2020 | 0.1203M |
| November 30, 2019 | 0.7067M |
| August 31, 2019 | 0.059M |
| May 31, 2019 | 1.243M |
| February 28, 2019 | 0.3813M |
| November 30, 2018 | 1.649M |
| August 31, 2018 | 0.5276M |
| May 31, 2018 | 0.332M |
| February 28, 2018 | 0.7252M |
| Date | Value |
|---|---|
| November 30, 2017 | 0.2824M |
| August 31, 2017 | 0.0977M |
| May 31, 2017 | 2.869M |
| February 28, 2017 | 0.8835M |
| November 30, 2016 | 0.1455M |
| August 31, 2016 | 0.3218M |
| May 31, 2016 | 0.1055M |
| February 29, 2016 | 0.051M |
| November 30, 2015 | 0.036M |
| August 31, 2015 | 0.0049M |
| May 31, 2015 | 0.4671M |
| February 28, 2015 | 0.00 |
| November 30, 2014 | -0.0987M |
| July 31, 2014 | -0.0988M |
| April 30, 2014 | 1.051M |
| January 31, 2014 | 0.08M |
| October 31, 2013 | -0.03M |
| July 31, 2013 | -0.0772M |
| April 30, 2013 | -0.0912M |
| January 31, 2013 | -0.1669M |
| October 31, 2012 | -0.0125M |
| July 31, 2012 | 0.05M |
| April 30, 2012 | 0.05M |
| January 31, 2012 | 0.20M |
| October 31, 2011 | -0.0346M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.1217M
Minimum
Aug 2023
9.435M
Maximum
Feb 2021
1.210M
Average
0.0295M
Median
Cash from Financing (Quarterly) Benchmarks
| Sunshine Biopharma Inc | -0.0305M |
| Acasti Pharma Inc | 0.00 |
| Aurinia Pharmaceuticals Inc | -5.577M |
| Edesa Biotech Inc | 0.2117M |
| Xenon Pharmaceuticals Inc | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.6196M |
| Cash from Investing (Quarterly) | -0.057M |
| Free Cash Flow | -5.408M |
| Free Cash Flow Per Share (Quarterly) | -0.0629 |
| Free Cash Flow to Equity (Quarterly) | -0.6766M |
| Free Cash Flow Yield | -19.98% |